Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue
Product sales	$ 6,190,698	$ 8,340,234
Licensing revenue	0	609,167
Total revenue	6,190,698	8,949,401
Cost of product sales	3,155,288	5,186,514
Gross profit	3,035,410	3,762,887
Operating expenses
Research and development	871,100	487,816
Sales and marketing	1,329,746	841,451
General and administrative	3,970,254	2,718,977
Total operating expenses	6,171,100	4,048,244
Operating loss	(3,135,690)	(285,357)
Other income (expenses)
Interest income	20,825	0
Interest expense	(177,308)	(742,219)
Amortization of deferred financing costs	(13,022)	(56,584)
Gain on disposal of property and equipment	4,400	0
Total other income (expenses)	(165,105)	(798,803)
Net Loss	(3,300,795)	(1,084,160)
Net loss attributable to non-controlling interest	83,045	0
Net Loss attributable to BioLife Solutions, Inc.	$ (3,217,750)	$ (1,084,160)
Basic and diluted net loss per common share	$ (0.31)	$ (0.22)
Basic and diluted weighted average common shares used to calculate net loss per common share	10,447,030	5,007,999